ArticleJournal of translational medicine2026
A pathology-to-single-cell framework links SPP1
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Spatiotemporal immune heterogeneity and precision immunotherapy for ovarian cancer.Clinical and translational medicine · 2026Review
- Multimodal integration of pathomics and single-cell transcriptomics reveals CDC20 as a link between prostate cancer recurrence and benzo[a]pyrene-responsive phenotypes.Frontiers in cell and developmental biology · 2026Article
- Neutrophil extracellular traps: the hidden driver of gastrointestinal cancer and emerging therapeutic strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeutrophil extracellular traps (NETs) facilitate hepatocellular carcinoma (HCC) progression, but the upstream cellular organizers and the histopathological correlates of NETosis-prone niches remain poorly defined. We aimed to build a pathology-to-single-cell framework to (i) quantify NETs-associated risk from routine whole-slide images (WSI) and (ii) nominate candidate organizer cells and mechanisms, focusing on SPP1+ M2 macrophages.
methodsWe integrated WSI, bulk transcriptomics, single-cell RNA-seq, spatial transcriptomics, and germline association data. NETs activity was quantified using gene-set scoring and aligned with WSI-derived morphology features (e.g. texture, stromal boundary disruption, and tumor–stroma interface complexity) to train and validate a prognostic model using regularized feature selection and survival machine learning. A 26,928-cell single-cell atlas was constructed to annotate macrophage states and neutrophil subsets, followed by trajectory inference to model macrophage polarization dynamics. Cell–cell communication was evaluated by ligand–receptor co-expression networks, and pathway/metabolic programs were inferred using multi-method enrichment and flux estimation. Spatial co-localization and neighborhood effects were assessed by deconvolution and spatial interaction modeling. Finally, network-based target prioritization was performed to highlight druggable nodes and candidate intervention pathways.
resultsThe WSI-derived NETs risk score stratified overall survival in training and validation cohorts (HR ≈ 8.48 and ≈6.44; AUC > 0.78). Multi-omics integration prioritized SPP1 as a central hub. SPP1+ M2 macrophages and NETs+ neutrophils preferentially localized at the tumor–stroma interface, where inferred communication converged on OPN(SPP1)–CD44/integrins and ICAM1–β2-integrin axes with downstream FAK–PI3K–Akt and NF-κB/MAPK signaling. Metabolic inference suggested a shared hypoxia/glycolysis–lactate–glutathione/antioxidant program in SPP1+ M2 macrophages mirrored by NETs+ neutrophils, consistent with a NETosis-permissive niche. Germline mapping indicated an antagonistic association pattern for the SPP1+ M2 program. Network prioritization highlighted SRC, AKT1, and CEBPB and pathways including ECM–receptor interaction, FAK/PI3K–Akt, MAPK, and TNF/IL-17.
conclusionsOur framework links routine pathology morphology to NETs activity and nominates SPP1+ M2 macrophages as candidate organizers of NETosis-prone high-risk niches in HCC. Importantly, the proposed macrophage–NETs axis is supported by convergent multi-omics/spatial evidence but remains primarily associative and inference-based, not definitive causation. Future work should include functional validation (e.g. macrophage–neutrophil co-culture NETosis assays, SPP1/CD44/integrin or ICAM1–ITGB2 perturbation, and in vivo depletion/blockade studies), prospective multi-center evaluation of the WSI risk score, and testing whether this axis generalizes beyond HCC or is liver-specific. These results provide a quantitative pathology-based risk stratification approach and a set of mechanistically plausible, targetable signaling–metabolic nodes for therapeutic exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.